Article
Telaprevir for retreatment of HCV infection.
The New England journal of medicine - 23 Jun 2011
Zeuzem Stefan, Andreone Pietro, Pol Stanislas, Lawitz Eric, Diago Moises, Roberts Stuart, Focaccia Roberto, Younossi Zobair, Foster Graham R, Horban Andrzej, Ferenci Peter, Nevens Frederik, Müllhaupt Beat, Pockros Paul, Terg Ruben, Shouval Daniel, van Hoek Bart, Weiland Ola, Van Heeswijk Rolf, De Meyer Sandra, Luo Don, Boogaerts Griet, Polo Ramon, Picchio Gaston, Beumont Maria
Abstract excerpt
BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin. METHODS: In this randomized, phase 3 trial, we evaluated the addition of telaprevir to peginterferon alfa-2a plus ribavirin in patients with HCV genotype 1 infection who had no response or a partial response to previous therapy or who had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.